Sinovac Biotech Ltd. (NASDAQ:SVA) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. Sinovac Biotech had a negative return on equity of 10.26% and a negative net margin of 17.94%. The business had revenue of $28.74 million for the quarter, compared to analyst estimates of $16.76 million. During the same period last year, the company earned ($0.01) EPS.

Shares of Sinovac Biotech (NASDAQ:SVA) opened at 6.14 on Wednesday. The stock has a 50 day moving average price of $6.07 and a 200-day moving average price of $5.95. Sinovac Biotech has a 12 month low of $4.38 and a 12 month high of $7.16. The company’s market capitalization is $349.58 million.

Earnings History for Sinovac Biotech (NASDAQ:SVA)

Separately, TheStreet lowered Sinovac Biotech from a “hold” rating to a “sell” rating in a research report on Wednesday, August 24th.

Several large investors have recently bought and sold shares of the company. Eqis Capital Management Inc. increased its stake in Sinovac Biotech by 4.5% in the second quarter. Eqis Capital Management Inc. now owns 228,350 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 9,794 shares in the last quarter. Credit Suisse AG increased its stake in shares of Sinovac Biotech by 48.2% in the third quarter. Credit Suisse AG now owns 89,428 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 29,085 shares during the period. GLG Partners LP bought a new stake in shares of Sinovac Biotech during the second quarter worth about $343,000. Panagora Asset Management Inc. increased its stake in shares of Sinovac Biotech by 4.7% in the second quarter. Panagora Asset Management Inc. now owns 42,816 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 1,929 shares during the period. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Sinovac Biotech by 5.6% in the second quarter. OMERS ADMINISTRATION Corp now owns 35,700 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 1,900 shares during the period. Institutional investors own 19.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be read at http://www.dailypolitical.com/2016/11/29/sinovac-biotech-ltd-sva-issues-quarterly-earnings-results.html.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

5 Day Chart for NASDAQ:SVA

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.